Clinical trial
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
NCT02559895 · Alder Biopharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT02559895 |
|---|---|
| Title | A Multicenter Assessment of ALD403 in Frequent Episodic Migraine |
| Official title | A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines |
| Acronym | PROMISE 1 |
| Lead sponsor | Alder Biopharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine Disorders |
| Intervention type | Drug |
| Interventions | ALD403, Placebo |
| Enrollment | 898 |
| Start date | Sep 1, 2015 |
| Primary completion | Feb 1, 2017 |
| Completion | Dec 1, 2017 |
| First posted | Sep 25, 2015 |
| Last update posted | May 14, 2020 |
| Countries | Georgia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: